TP53 and vulva cancer: In order to personalize therapeutic options or adjunctive therapies for vulvar cancer, the exploration of the main molecular venues involved in the pathogenesis of vulvar carcinoma represents an active field of research, mainly focusing on aberrant cell cycle activity as a common pathway in all vulvar cancers, characterized by the overexpression of p53, Rb, cyclin D1, as well as the deregulation of EGFR expression or angiogenesis.